Crossmark

The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046

Crossref DOI link: https://doi.org/10.1007/s10637-022-01259-x

Published Online: 2022-05-25

Published Print: 2022-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Repetto, Matteo

Crimini, Edoardo https://orcid.org/0000-0002-1869-0607
Ascione, Liliana

Boscolo Bielo, Luca

Belli, Carmen

Curigliano, Giuseppe
License Information

Text and Data Mining valid from 2022-05-25

Version of Record valid from 2022-05-25
More Information

Article History

Received: 24 January 2022

Accepted: 16 May 2022

First Online: 25 May 2022

Declarations

:

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: GC: Consultancy with Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Foundation Medicine, GlaxoSmithKline, Lilly, Novartis, Pfizer, Roche/Genentech, Samsung, and Seagen Inc.; honoraria from Ellipses Pharma; research funding/grants from Merck; speaker’s bureau with Daiichi Sankyo, Foundation Medicine, Lilly, Novartis, Pfizer, Roche/Genentech, Samsung, and Seagen Inc.; travel from Pfizer and Roche/Genentech. Other authors have no conflicts of interest to declare.

Document is current

Any future updates will be listed below